Tiziana Life Sciences Ltd (NasdaqCM: TLSA)
Health Care · Biotechnology · GB
$1.15
+0.88% today · -41.8% 1Y
Tiziana Life Sciences Ltd (NasdaqCM: TLSA) operates in the Biotechnology industry within the Health Care sector. The company is valued at $147.41M and employs 10 people.
Over the last twelve months the share price has lost 41.8%, trading between 0.87 and 2.35.
Tweenvest scores Tiziana Life Sciences Ltd across four factors: quality 19/100. Its strongest factor is quality.
TLSA price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $147.41M
- Revenue (TTM)
- —
- P/E
- —
- EPS
- -0.16
- Dividend yield
- —
- Beta (5Y)
- 0.46
- 52-week high
- $2.35
- 52-week low
- $0.87
- Avg volume (3M)
- —
- Shares outstanding
- 129.31M
- Employees
- 10
- Next earnings
- —
About Tiziana Life Sciences Ltd
Tiziana Life Sciences Ltd is a biotechnology firm dedicated to the research and advancement of novel molecular therapies for human ailments, particularly within oncology and immunology. Its flagship immunology program features Foralumab (TZLS-401), a human anti-CD3 monoclonal antibody under development for a range of conditions including Crohn's disease, graft versus host disease, ulcerative colitis, multiple sclerosis, type-1 diabetes, inflammatory bowel disease, psoriasis, and rheumatoid arthritis. Additionally, the company is progressing Milciclib (TZLS-201), a small molecule inhibitor that targets multiple cyclin-dependent, tropomycin receptor, and Src family kinases to suppress abnormal cell growth and cancer progression. Another significant asset is anti-Interleukin 6 receptor (IL6R) mAb (TZLS-501), a fully human monoclonal antibody intended to mitigate IL6-induced inflammation and treat COVID-19 patients. Founded in 1998, Tiziana Life Sciences is based in London, United Kingdom.
- ISIN
- BMG889121031
- Listed since
- Nov 20, 2018
- Exchange
- Nasdaq Capital Market
- Currency
- USD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| AbbVie Inc.NYSE: ABBV | $467.44B | $264.52 | -0.17% |
| Amgen Inc.NasdaqGS: AMGN | $239.95B | $445.03 | +0.27% |
| Gilead Sciences, Inc.NasdaqGS: GILD | $181.95B | $146.74 | +0.42% |
| Vertex Pharmaceuticals IncorporatedNasdaqGS: VRTX | $138.79B | $547.59 | -0.08% |
| Regeneron Pharmaceuticals, Inc.NasdaqGS: REGN | $82.73B | $828.50 | -0.66% |
| argenx SEENXTBR: ARGX | $63.06B | €874.40 | +1.18% |
| CSL LimitedASX: CSL | $57.94B | AU$169.11 | +0.48% |
| Moderna, Inc.NasdaqGS: MRNA | $55.45B | $142.34 | +2.48% |
Figures last refreshed Aug 18, 2026.